Is Pola-R-CHP a suitable standard for all or should the lack of survival benefit and differential subgroup responses give pause in treating all patients who qualify?

HealthDay News — The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) are compared in a systematic literature review and network ...

For nearly two decades, one wife and her husband tried everything to have a child. Their lives became a cycle of appointments ...